ProFibrix News


THE MEDICINES COMPANY ANNOUNCES POSITIVE PHASE III TRIAL RESULTS FOR FIBROCAPS; COMPLETES
PROFIBRIX ACQUISITION

In Phase III trial, FINISH-3, Fibrocaps meets all pre-specified endpoints

MAA filing anticipated in Europe (Q4 2013); BLA filing anticipated in U.S. (Q1 2014)

The Medicines Company builds on existing hemostasis franchise



THE MEDICINES COMPANY SIGNS AGREEMENT TO ACQUIRE PROFIBRIX

Affirms The Medicines Company’s presence in surgical hemostasis

ProFibrix lead product Fibrocaps expected to deliver Phase 3 data third quarter 2013

Highlights The Medicines Company’s long term commitment to recombinant proteins



ProFibrix Completes Patient Enrolment in Pivotal Phase III with FibrocapsTM and Reports Positive Feedback from Surgical Community

Company remains on track for 2013 filings in US and Europe

Inspired by Nature, with Science as our Tool, we create Innovative Healthcare Products.

ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the field of hemostasis. Fibrocaps™, the proposed name of the company’s lead biologic, is being studied to help stop bleeding during surgery and after trauma injury. A dry powder based on a mixture of fibrinogen and thrombin, Fibrocaps is a ready-to-use preparation designed to be stable at room temperature and applied in different formats, including sprays and bandages.